Highest-materiality recent filing
Tvardi Q1 net loss narrows to $6.8M; TTI-109 data due June, TTI-101 HCC data 2H 2026
Net loss of $6.8M ($0.73 per share) vs $9.6M ($3.72) in Q1 2025; R&D spend rose to $4.9M.
Tvardi reports 2025 net loss $18.2M; cash to fund into Q4 2026; key clinical milestones ahead
Net loss for 2025 was $18.2M ($2.46 basic EPS); cash $30.8M expected to fund operations into Q4 2026.
Tvardi Therapeutics announces June 9, 2026 annual meeting; sets proposal deadlines
Annual meeting of stockholders scheduled for June 9, 2026.
Tvardi Therapeutics posts updated corporate presentation on website
Presentation available on company website as of January 16, 2026.
Tvardi grants retention stock options to CEO, CMO, CFO; adopts severance plan
Board approved one-time retention options: CEO Imran Alibhai 47,500, CMO John Kauh 17,500, CFO Dan Conn 17,500 shares.
Tvardi Therapeutics posts updated corporate presentation on Nov 19, 2025; full details unavailable
Corporate presentation is available on company's website as of November 19, 2025.
Tvardi Q3 net loss $5.5M; IPF trial fails, HCC data due H1 2026
Q3 net loss of $5.5M ($0.59/share), roughly flat YoY; cash $36.5M, runway into Q4 2026.
Tvardi Therapeutics Phase 2 IPF trial misses endpoints; no benefit from TTI-101
Trial did not meet goals; no statistically significant difference between TTI-101 and placebo on FVC change.
Tvardi Therapeutics Q2 net income $4.2M; IPF Phase 2 topline data on track for Q4 2025
Net income of $4.2M vs. net loss of $7.0M in Q2 2024; driven by $12.8M remeasurement gain on convertible notes.
Director Shaheen Wirk resigns from Tvardi Therapeutics board, no disagreement cited
Shaheen Wirk resigned from the Board of Directors on July 8, 2025.
Tvardi Therapeutics posts updated corporate presentation; no specific new data disclosed in filing
Company updated corporate presentation and posted it on investor relations website as of June 6, 2025.
Tvardi completes enrollment in Phase 2 IPF trial of TTI-101; topline data Q4 2025
Completed enrollment in REVERT IPF Phase 2 trial of oral STAT3 inhibitor TTI-101 for idiopathic pulmonary fibrosis.
Tvardi Q1 2025 net loss $9.6M, cash burn $7.7M; going concern doubt persists
Net loss $9.6M ($0.50 dil EPS) vs $4.2M loss in Q1 2024; accumulated deficit $101.8M.
Tvardi completes merger with Cara, switches auditor to Deloitte, cash into 2H 2026
Completed merger with Cara Therapeutics; received ~$23.8M net cash; cash runway expected into 2H 2026.
Cara-Tvardi merger closes, new company renamed Tvardi Therapeutics (TVRD)
Merger completed April 15, 2025: Merger Sub merged into Tvardi, which became a wholly owned subsidiary.
Cara Therapeutics issues investor deck for pending merger with Tvardi (STAT3 fibrosis program)
Merger with Tvardi Therapeutics (STAT3 inhibitor developer for fibrosis) announced Dec 17, 2024; closing conditions remain.
Cara stockholders approve all six merger proposals with Tvardi; Tvardi posts $29.4M net loss
All proposals passed: stock issuance for merger (2,088,293 for), equity plan, ESPP, reverse split (1:2-1:4), authorized shares increase to 150M, and advisory compensation.
Cara issues supplemental disclosures for Tvardi merger after stockholder lawsuits
Received 13 demands and 2 lawsuits (filed Mar 5-6, 2025) claiming proxy omitted material info.
Cara Therapeutics files investor presentation for proposed merger with Tvardi
Furnishes investor presentation (Exhibit 99.1) for post-combination company with Tvardi, a STAT3-targeted fibrosis biopharma.
Nasdaq bid price compliance regained; equity compliance deadline extended to May 19
Cara regained Nasdaq minimum bid price compliance after 1-for-12 reverse stock split effective Dec 30; letter received Jan 16.
Effective 5:00 p.m. ET Dec 30, 2024; trading on split-adjusted basis begins Dec 31, 2024.
Merger agreement with Tvardi Therapeutics and merger sub was signed on December 17, 2024.
Cara Therapeutics to Merge with Tvardi Therapeutics and Sell Difelikefalin Assets to CSL Vifor
Cara enters Merger Agreement with Tvardi; pre-Merger Cara holders will own ~15.25%, Tvardi holders ~12.54%, convertible note holders ~72.21% of combined company.
Stockholders' equity of $707,000 at Sep 30, 2024 is below Nasdaq's $2.5 million minimum.
Nasdaq granted 180-day extension, until January 27, 2025, to meet minimum $1.00 closing bid price for 10 consecutive business days.
Cara Therapeutics cuts workforce 70% after discontinuing NP program, explores strategic alternatives
Board approved streamlined operating plan and strategic alternatives after discontinuing NP program following KOURAGE-1 Part A results on June 12, 2024.
Cara Therapeutics discontinues NP program after oral difelikefalin fails Part A of KOURAGE-1 study
Oral difelikefalin did not demonstrate meaningful clinical benefit at any dose vs. placebo in Part A of KOURAGE-1 study for notalgia paresthetica.
CARA shareholders approve doubling authorized shares and authorize reverse stock split
Authorized common stock increased from 100M to 200M shares; 76.5% of votes in favor.
Cara Therapeutics Q1 2024 net loss $0.56/shr, revenue $2.1M; NP data by end 2Q24
Net loss $30.7M ($0.56/shr) vs $26.7M ($0.49) in Q1 2023; total revenue $2.1M down from $6.2M.
Cara Therapeutics CMO Joana Goncalves resigns effective April 16, 2024
Dr. Joana Goncalves notified Company of resignation on March 19, 2024.
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
Sujal Shah was appointed to the Company’s board of directors and as Chair of our board of directors upon the closing of the Merger.
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
the size of the Company’s board of directors will be fixed at seven members consisting of one member designated by Cara, who is Susan Shiff, Ph.D., and six members designated by Tvardi, who are Sujal Shah, Michael Wyzga, Wallace Hall, Shaheen Wirk, M.D., Imran Alibhai, Ph.D., and Cynthia Smith.
Martin Vogelbaum, Christopher Posner, Helen M. Boudreau, Jeffrey Ives, Ph.D., and Lisa von Moltke, M.D. resigned from the Company’s board of directors
Max materiality 0.90 · Median 0.68 · Most common event other_material